Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Income from Continuing Operations (2016 - 2026)

Champions Oncology has reported Income from Continuing Operations over the past 17 years, most recently at 279000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 106.21% year-over-year to 279000.0; the TTM value through Jan 2026 reached 2343000.0, down 136.46%, while the annual FY2025 figure was 4701000.0, 164.61% up from the prior year.
  • Income from Continuing Operations for Q1 2026 was 279000.0 at Champions Oncology, down from 237000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 4495000.0 in Q1 2025 and troughed at 2566000.0 in Q3 2023.
  • A 5-year average of 469117.65 and a median of 319000.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: crashed 12843.75% in 2023 and later skyrocketed 277.67% in 2025.
  • Year by year, Income from Continuing Operations stood at 16000.0 in 2022, then crashed by 12843.75% to 2071000.0 in 2023, then surged by 135.15% to 728000.0 in 2024, then tumbled by 67.45% to 237000.0 in 2025, then plummeted by 217.72% to 279000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for CSBR at 279000.0 in Q1 2026, 237000.0 in Q4 2025, and 466000.0 in Q3 2025.